Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MC5R | P33032 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010806 | 0.82 | TDP1 (0.48) | NPC1RAB9ACYP2C19CYP1A2CYP2C9 | |
| SCHEMBL7359545 | 0.79 | TDP1 (0.43) | NPC1RAB9ACYP2C19CYP1A2CYP2C9 | |
| SCHEMBL10806504 | 0.79 | L3MBTL1 (0.54) | NPC1RAB9AALDH1A1L3MBTL1MEN1 | |
| SCHEMBL5551802 | 0.75 | MC5R (0.58) | MAPK1MC5RNPC1RAB9ACYP2C19 | |
| SCHEMBL8204171 | 0.74 | RELA (0.53) | MAPK1RAB9ACYP1A2RELAKDM4E | |
| SCHEMBL8668861 | 0.74 | RAB9A (0.51) | MC5RRAB9ACYP1A2RELAKDM4E | |
| SCHEMBL8671357 | 0.74 | CYP1A2 (0.48) | NPC1RAB9ACYP2C19CYP1A2CYP2C9 | |
| SCHEMBL5500901 | 0.74 | RAB9A (0.41) | MAPK1MC5RNPC1RAB9ACYP2C19 | |
| SCHEMBL5830944 | 0.73 | CYP2C19 (0.56) | NPC1RAB9ACYP2C19CYP1A2CYP2C9 | |
| SCHEMBL140015 | 0.71 | RELA (0.54) | RAB9ACYP1A2RELAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448956-B1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NAT RECH SCIENT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9206222-B2 | Solid phase peptide synthesis of peptide alcohols | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-12-08 | — | — | US | disclosed |
| EP-2448956-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | Centre National De La Recherche Scientifique CNRS (FR) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-03 | — | — | US | disclosed |
| WO-2011000848-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270025-A1 | Solid phase peptide synthesis of peptide alcohols | Centre National pour la Recherche Scientifique (CNRS) (FR) | 2011-01-05 | — | — | EP | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-6753409-B1 | FOR TREATMENT OF MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERIAL DISEASE AND DISSEMINATED INTRAVASCULAR COAGULATION | AVENTIS PHARMACEUTICALS INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1030831-A4 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARM PROD INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | AVENTIS PHARMACEUTICALS INC. | 2002-01-03 | — | — | US | disclosed |
| EP-0929572-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0923553-A1 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N- N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1999019294-A1 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. LEGAL/PATENTS (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0812205-A4 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5866685-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5780590-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998017678-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998007696-A1 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-[N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| EP-0812205-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1995010295-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | PLAT, SELP, PIGS | MAPK1 3313/4885MC5R 2369/4885NPC1 3858/4885 |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | VIP, ERG28, PSAP | MAPK1 2201/4885MC5R 4023/4885NPC1 1717/4885 |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MAPK1 2616/4885MC5R 1933/4885NPC1 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.